Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
EAST RUTHERFORD, N.J., May 15, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at the 2017 UBS Global Healthcare Conference on May 22, 2017 at 10:30 a.m. EDT in New York City.
The live audio webcast and slide presentation can be accessed from the Cambrex website at www.cambrex.com in the Investors section under “Webcasts & Presentations”, and a replay will be available for 90 days after the live event concludes.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura IR Associate Tel: +201 804 3037 Email: [email protected]
